Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
Editor's Choice
DIABETOLOGY / CLINICAL RESEARCH
The use of sodium-glucose cotransporter 2 inhibitors and the incidence of uveitis in type 2 diabetes: a population-based cohort study
1
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
2
Department of Radiology, Taichung Veterans General Hospital, Taichung, Taiwan
3
Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan
4
School of Medicine, Chung Shan Medical University, Taichung, Taiwan
5
Department of Ophthalmology, Nobel Eye Institute, Taipei, Taiwan
6
Department of Optometry, Da-Yeh University, Chunghua, Taiwan
7
Department of Ophthalmology, Jen-Ai Hospital Dali Branch, Taichung, Taiwan
8
Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan
9
Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan
10
Departments of Ophthalmology, Sijhih Cathay General Hospital, New Taipei City, Taiwan
11
School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan
Submission date: 2023-08-02
Final revision date: 2023-10-06
Acceptance date: 2023-10-17
Online publication date: 2024-02-26
Arch Med Sci 2024;20(2):402-409
KEYWORDS
TOPICS
ABSTRACT
Introduction:
To survey the potential correlation between the application of sodium-glucose cotransporter 2 (SGLT2) inhibitors and the incidence of uveitis in individuals with type 2 diabetes mellitus (T2DM).
Material and methods:
A retrospective cohort study using the National Health Insurance Research Database (NHIRD) was conducted. The T2DM patients using SGLT2 inhibitors and those taking other anti-diabetic medications were assigned to the SGLT2 group and the control group, respectively, with a 1 : 2 ratio via the propensity score-matching (PSM) method. The major outcome in this study is the development of uveitis according to the diagnostic codes. The Cox proportional hazard regression was adopted to yield the adjusted hazard ratio (aHR) with 95% confidence interval (CI) between the groups.
Results:
There were 147 and 371 new uveitis episodes in the SGLT2 and control groups after the follow-up period up to 5 years. The incidence of uveitis in the SGLT2 group (aHR = 0.736, 95% CI: 0.602–0.899, p = 0.0007) was significantly lower than that in the control group after adjusting for the effect of all the confounders. In the subgroup analyses, the SGLT2 inhibitors showed a higher correlation with low uveitis incidence in T2DM patients aged under 50 than T2DM individuals aged over 50 years (p = 0.0012), while the effect of SGLT2 inhibitors on the incidence of anterior and posterior uveitis development was similar (p = 0.7993).
Conclusions:
The use of SGLT2 inhibitors could be an independent protective factor for uveitis development in T2DM population.
To survey the potential correlation between the application of sodium-glucose cotransporter 2 (SGLT2) inhibitors and the incidence of uveitis in individuals with type 2 diabetes mellitus (T2DM).
Material and methods:
A retrospective cohort study using the National Health Insurance Research Database (NHIRD) was conducted. The T2DM patients using SGLT2 inhibitors and those taking other anti-diabetic medications were assigned to the SGLT2 group and the control group, respectively, with a 1 : 2 ratio via the propensity score-matching (PSM) method. The major outcome in this study is the development of uveitis according to the diagnostic codes. The Cox proportional hazard regression was adopted to yield the adjusted hazard ratio (aHR) with 95% confidence interval (CI) between the groups.
Results:
There were 147 and 371 new uveitis episodes in the SGLT2 and control groups after the follow-up period up to 5 years. The incidence of uveitis in the SGLT2 group (aHR = 0.736, 95% CI: 0.602–0.899, p = 0.0007) was significantly lower than that in the control group after adjusting for the effect of all the confounders. In the subgroup analyses, the SGLT2 inhibitors showed a higher correlation with low uveitis incidence in T2DM patients aged under 50 than T2DM individuals aged over 50 years (p = 0.0012), while the effect of SGLT2 inhibitors on the incidence of anterior and posterior uveitis development was similar (p = 0.7993).
Conclusions:
The use of SGLT2 inhibitors could be an independent protective factor for uveitis development in T2DM population.
REFERENCES (40)
1.
Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol 2020; 18: 104-9.
2.
Cho YK, Kang YM, Lee SE, et al. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2018; 44: 393-401.
3.
Mitrovic B, Gluvic ZM, Obradovic M, et al. Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? Arch Med Sci 2023; 19: 884-94.
4.
Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health 2019; 16: 2965.
5.
Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022; 21: 83.
6.
Bernardi M, Spadafora L, Galli M, Biondi-Zoccai G, Sabouret P. Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients? Arch Med Sci 2023; 19: 528-31.
7.
Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2018; 20: 1972-6.
8.
Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 2021; 83: 503-28.
9.
Jiang K, Xu Y, Wang D, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell 2022; 13: 336-59.
10.
Karagiannis T, Tsapas A, Athanasiadou E, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2021; 174: 108737.
11.
van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 2022; 18: 294-306.
12.
Li C, Zhou Z, Neuen BL, et al. Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2021; 23: 252-7.
13.
Zhou B, Shi Y, Fu R, et al. Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 2022; 13: 907340.
14.
Sha W, Wen S, Chen L, Xu B, Lei T, Zhou L. The role of SGLT2 inhibitor on the treatment of diabetic retinopathy. J Diabetes Res 2020; 2020: 8867875.
15.
Mudaliar S, Hupfeld C, Chao DL. SGLT2 inhibitor-induced low-grade ketonemia ameliorates retinal hypoxia in diabetic retinopathy-a novel hypothesis. J Clin Endocrinol Metab 2021; 106: 1235-44.
16.
Herat LY, Matthews JR, Ong WE, Rakoczy EP, Schlaich MP, Matthews VB. Determining the role of SGLT2 inhibition with dapagliflozin in the development of diabetic retinopathy. Front Biosci (Landmark Ed) 2022; 27: 321.
17.
Ma Y, Lin C, Cai X, et al. The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2022; 15: 877-86.
18.
Cho EH, Park SJ, Han S, Song JH, Lee K, Chung YR. Potent oral hypoglycemic agents for microvascular complication: sodium-glucose cotransporter 2 inhibitors for diabetic retinopathy. J Diabetes Res 2018; 2018: 6807219.
19.
Su YC, Hung JH, Chang KC, et al. Comparison of sodium-glucose cotransporter 2 inhibitors vs glucagonlike peptide-1 receptor agonists and incidence of dry eye disease in patients with type 2 diabetes in Taiwan. JAMA Netw Open 2022; 5: e2232584.
20.
Pan LY, Kuo YK, Chen TH, Sun CC. Dry eye disease in patients with type II diabetes mellitus: a retrospective, population-based cohort study in Taiwan. Front Med (Lausanne) 2022; 9: 980714.
21.
Sève P, Cacoub P, Bodaghi B, et al. Uveitis: diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmun Rev 2017; 16: 1254-64.
22.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 2020; 17: 761-72.
23.
Komatsu S, Nomiyama T, Numata T, et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J 2020; 67: 99-106.
24.
Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotective effect of SGLT2 inhibitors. Molecules 2021; 26: 7213.
25.
Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci 2022; 23: 3651.
26.
Nelinson DS, Sosa JM, Chilton RJ. SGLT2 inhibitors: a narrative review of efficacy and safety. J Osteopath Med 2021; 121: 229-39.
27.
Ma L, Zou R, Shi W, et al. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics 2022; 12: 5034-50.
28.
Long Q, Li L, Yang H, et al. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol 2022; 110: 109024.
29.
Yang Z, Li T, Xian J, et al. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2 signaling pathway in arrhythmogenic cardiomyopathy. FASEB J 2022; 36: e22410.
30.
Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists. Int J Mol Sci 2021; 22: 10822.
32.
Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 2019; 18: 15.
33.
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014; 105: 141-50.
34.
Nakamura Y, Nagai Y, Terashima Y, et al. Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes. Expert Opin Pharmacother 2015; 16: 2553-9.
35.
Han SB, Yang HK, Hyon JY. Influence of diabetes mellitus on anterior segment of the eye. Clin Interv Aging 2019; 14: 53-63.
36.
Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 2020; 141: 1227-34.
37.
Butler J, Packer M, Filippatos G, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 2022; 43: 416-26.
38.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50.
39.
Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm 2018; 26: 2-16.
40.
Oh BL, Lee JS, Lee EY, Lee HY, Yu HG. Incidence and risk factors for blindness in uveitis: a nationwide cohort study from 2002 to 2013. Ocul Immunol Inflamm 2021; 29: 1040-4.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
